)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Neem's Hill
Neem's Hill (NEEMS) investor relations material
Neem's Hill Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 net sales were 3,376 KSEK vs 3,324 KSEK YoY; 9M sales were 9,466 KSEK vs 9,637 KSEK, all from Animal Care.
Q3 net loss was 1,291 KSEK vs 1,267 KSEK; 9M net loss was 5,486 KSEK vs 5,532 KSEK.
Treatment-kit sales continued to grow as installed vetlQure systems were used more frequently; more than 60 systems were installed globally and over 4,500 Animal Care treatments sold since launch.
Financial highlights
Q3 operating loss was 1,097 KSEK vs 1,065 KSEK; 9M operating loss was 4,460 KSEK vs 4,322 KSEK.
Q3 external costs rose to 4,116 KSEK from 3,207 KSEK, reflecting sales and marketing capacity added since June, seasonal conferences, and one-off consultant and financial/legal advisory costs.
Q3 operating cash outflow was 2,470 KSEK vs 1,663 KSEK; 9M operating cash outflow was 5,393 KSEK vs 3,406 KSEK.
Outlook and guidance
Priorities are converting expanded commercial reach into new installations and helping more clinics establish regular treatment activity; positive cash flow remains a key objective.
Human Care development in India may advance through selected clinical projects, subject to available funding, clinical partnerships, and an agreed plan.
North American technical services, logistics, and administration may be strengthened, with any expansion paced to available funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neem's Hill
- Recurring revenue up 52% in H1 2026 as TSE adoption and clinical activity accelerate.NEEMS
Q2 2026 - Record Q1 sales and improved profitability driven by Animal Care and operational discipline.NEEMSQ1 2026
- Revenue doubled and losses narrowed, with Animal Care driving growth and TSE validated.NEEMSQ4 2025
- Strong Q3 revenue growth and record Animal Care sales drive improved financials and outlook.NEEMSQ3 2025
- Animal Care sales hit records and TSE tech achieved scientific validation, fueling growth.NEEMSQ2 2025
- Animal Care sales drove improved results, but continued financing is required for growth.NEEMSQ3 2024
- Q2 2024 saw record sales, narrowed losses, and a successful rights issue boosting liquidity.NEEMSQ2 2024
- Animal Care sales surged and global reach expanded, but funding needs remain.NEEMSQ1 2025
- Record sales and improved results in 2024, led by Animal Care's strong performance.NEEMSQ4 2024
Next Neem's Hill earnings date
Q4 202623 Feb, 2027
Neem's Hill
Next Neem's Hill earnings date
Q4 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Neem's Hill AB is a medical technology company specializing in innovative treatment solutions for cancer and chronic pain. The company develops and markets therapies based on its patented Tumor-Specific Electroporation (TSE) technology, designed to enhance the effectiveness of chemotherapy for specific cancers. Its products are intended to provide minimally invasive and targeted treatments.